Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
Anticipate generic drug launch
Manage your formulary budget
Proactively manage your pharmacy inventory
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Modulators of ATP-binding cassette transporters|
|Abstract:||Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.|
|Inventor(s):||Hadida Ruah; Sara S. (La Jolla, CA), Hamilton; Matthew (Hackettstown, NJ), Miller; Mark (San Diego, CA), Grootenhuis; Peter D. J. (San Diego, CA), Bear; Brian (Carlsbad, CA), McCartney; Jason (Cardiff by the Sea, CA), Zhou; Jinglan (San Diego, CA)|
|Assignee:||Vertex Pharmaceuticals Incorporated (Boston, MA)|
1. A method of treating cystic fibrosis in a patient, wherein the patient has a defective gene that causes a deletion of phenylalanine at position 508 of the cystic fibrosis
transmembrane conductance regulator amino acid sequence, said method comprising the step of administering to the patient an effective amount of the compound ##STR00524## or a pharmaceutically acceptable salt thereof.
2. The method of claim 1, wherein the patient has two copies of the defective gene.
3. A method of treating cystic fibrosis in a patient, wherein the patient has a defective gene that causes a deletion of phenylalanine at position 508 of the cystic fibrosis transmembrane conductance regulator amino acid sequence, said method comprising the step of administering to said patient an effective amount of a composition comprising: i) the compound: ##STR00525## or a pharmaceutically acceptable salt thereof; and ii) a pharmaceutically acceptable carrier.
4. The method of claim 3, wherein the patient has two copies of the defective gene.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.